Cargando…

Research progress of nanovaccine in anti-tumor immunotherapy

Tumor vaccines aim to activate dormant or unresponsive tumor-specific T lymphocytes by using tumor-specific or tumor-associated antigens, thus enhancing the body’s natural defense against cancer. However, the effectiveness of tumor vaccines is limited by the presence of tumor heterogeneity, low immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Min, Liu, Xiyu, Qian, Zhangbo, Fan, Dianfa, Sun, Xinjun, Zhong, Liping, Wu, Pan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484753/
https://www.ncbi.nlm.nih.gov/pubmed/37692854
http://dx.doi.org/10.3389/fonc.2023.1211262
_version_ 1785102650863255552
author Yao, Min
Liu, Xiyu
Qian, Zhangbo
Fan, Dianfa
Sun, Xinjun
Zhong, Liping
Wu, Pan
author_facet Yao, Min
Liu, Xiyu
Qian, Zhangbo
Fan, Dianfa
Sun, Xinjun
Zhong, Liping
Wu, Pan
author_sort Yao, Min
collection PubMed
description Tumor vaccines aim to activate dormant or unresponsive tumor-specific T lymphocytes by using tumor-specific or tumor-associated antigens, thus enhancing the body’s natural defense against cancer. However, the effectiveness of tumor vaccines is limited by the presence of tumor heterogeneity, low immunogenicity, and immune evasion mechanisms. Fortunately, multifunctional nanoparticles offer a unique chance to address these issues. With the advantages of their small size, high stability, efficient drug delivery, and controlled surface chemistry, nanomaterials can precisely target tumor sites, improve the delivery of tumor antigens and immune adjuvants, reshape the immunosuppressive tumor microenvironment, and enhance the body’s anti-tumor immune response, resulting in improved efficacy and reduced side effects. Nanovaccine, a type of vaccine that uses nanotechnology to deliver antigens and adjuvants to immune cells, has emerged as a promising strategy for cancer immunotherapy due to its ability to stimulate immune responses and induce tumor-specific immunity. In this review, we discussed the compositions and types of nanovaccine, and the mechanisms behind their anti-tumor effects based on the latest research. We hope that this will provide a more scientific basis for designing tumor vaccines and enhancing the effectiveness of tumor immunotherapy.
format Online
Article
Text
id pubmed-10484753
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104847532023-09-09 Research progress of nanovaccine in anti-tumor immunotherapy Yao, Min Liu, Xiyu Qian, Zhangbo Fan, Dianfa Sun, Xinjun Zhong, Liping Wu, Pan Front Oncol Oncology Tumor vaccines aim to activate dormant or unresponsive tumor-specific T lymphocytes by using tumor-specific or tumor-associated antigens, thus enhancing the body’s natural defense against cancer. However, the effectiveness of tumor vaccines is limited by the presence of tumor heterogeneity, low immunogenicity, and immune evasion mechanisms. Fortunately, multifunctional nanoparticles offer a unique chance to address these issues. With the advantages of their small size, high stability, efficient drug delivery, and controlled surface chemistry, nanomaterials can precisely target tumor sites, improve the delivery of tumor antigens and immune adjuvants, reshape the immunosuppressive tumor microenvironment, and enhance the body’s anti-tumor immune response, resulting in improved efficacy and reduced side effects. Nanovaccine, a type of vaccine that uses nanotechnology to deliver antigens and adjuvants to immune cells, has emerged as a promising strategy for cancer immunotherapy due to its ability to stimulate immune responses and induce tumor-specific immunity. In this review, we discussed the compositions and types of nanovaccine, and the mechanisms behind their anti-tumor effects based on the latest research. We hope that this will provide a more scientific basis for designing tumor vaccines and enhancing the effectiveness of tumor immunotherapy. Frontiers Media S.A. 2023-08-24 /pmc/articles/PMC10484753/ /pubmed/37692854 http://dx.doi.org/10.3389/fonc.2023.1211262 Text en Copyright © 2023 Yao, Liu, Qian, Fan, Sun, Zhong and Wu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yao, Min
Liu, Xiyu
Qian, Zhangbo
Fan, Dianfa
Sun, Xinjun
Zhong, Liping
Wu, Pan
Research progress of nanovaccine in anti-tumor immunotherapy
title Research progress of nanovaccine in anti-tumor immunotherapy
title_full Research progress of nanovaccine in anti-tumor immunotherapy
title_fullStr Research progress of nanovaccine in anti-tumor immunotherapy
title_full_unstemmed Research progress of nanovaccine in anti-tumor immunotherapy
title_short Research progress of nanovaccine in anti-tumor immunotherapy
title_sort research progress of nanovaccine in anti-tumor immunotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484753/
https://www.ncbi.nlm.nih.gov/pubmed/37692854
http://dx.doi.org/10.3389/fonc.2023.1211262
work_keys_str_mv AT yaomin researchprogressofnanovaccineinantitumorimmunotherapy
AT liuxiyu researchprogressofnanovaccineinantitumorimmunotherapy
AT qianzhangbo researchprogressofnanovaccineinantitumorimmunotherapy
AT fandianfa researchprogressofnanovaccineinantitumorimmunotherapy
AT sunxinjun researchprogressofnanovaccineinantitumorimmunotherapy
AT zhongliping researchprogressofnanovaccineinantitumorimmunotherapy
AT wupan researchprogressofnanovaccineinantitumorimmunotherapy